Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q2WGJ9

UPID:
FR1L6_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q2WGJ9

BACKGROUND:
The Fer-1-like protein 6, with its unique identifier Q2WGJ9, is a protein of interest in the realm of molecular biology. Despite the absence of detailed functional annotations, preliminary data suggest its involvement in critical cellular functions. This protein's role, though not fully understood, is anticipated to be significant in maintaining cellular integrity and function.

THERAPEUTIC SIGNIFICANCE:
The investigation into Fer-1-like protein 6's biological roles holds promise for uncovering new therapeutic avenues. The absence of direct links to specific diseases does not diminish its potential impact on drug discovery. By elucidating its functions, scientists are poised to identify novel targets for therapeutic intervention, paving the way for groundbreaking treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.